An immune-based risk-stratification system for predicting prognosis in pulmonary sarcomatoid carcinoma (PSC)

References

• Yang Z, Xu J, Li L, Li R, Wang Y, Tian Y, Guo W, Wang Z, Tan F, Ying J, et al.. Integrated molecular characterization reveals potential therapeutic strategies for pulmonary sarcomatoid carcinoma. Nature Communications. 2020;11(1):4878. doi:10.1038/s41467-020-18702-3.
   PubMed Web of Science ®Google Scholar
• Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, Chirieac LR, Dacic S, Duhig E, Flieder DB, et al.. The 2015 world health organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer. 2015;10(9):1243–16. doi:10.1097/JTO.0000000000000630.
   PubMed Web of Science ®Google Scholar
• Huang S-Y, Shen S-J, Li X-Y. Pulmonary sarcomatoid carcinoma: a clinicopathologic study and prognostic analysis of 51 cases. World Journal of Surgical Oncology. 2013;11(1):252. doi:10.1186/1477-7819-11-252.
   PubMed Web of Science ®Google Scholar
• Martin LW, Correa AM, Ordonez NG, Roth JA, Swisher SG, Vaporciyan AA, Walsh GL, Rice DC. Sarcomatoid carcinoma of the lung: a predictor of poor prognosis. The Annals of Thoracic Surgery. 2007;84(3):973–980. doi:10.1016/j.athoracsur.2007.03.099.
   PubMed Web of Science ®Google Scholar
• Roesel C, Terjung S, Weinreich G, Hager T, Chalvatzoulis E, Metzenmacher M, Welter S. Sarcomatoid carcinoma of the lung: a rare histological subtype of non-small cell lung cancer with a poor prognosis even at earlier tumour stages. Interactive CardioVascular and Thoracic Surgery. 2016;24:407–413.
   Web of Science ®Google Scholar
• Rahouma M, Kamel M, Narula N, Nasar A, Harrison S, Lee B, Stiles B, Altorki NK, Port JL. Pulmonary sarcomatoid carcinoma: an analysis of a rare cancer from the Surveillance, Epidemiology, and End Results database†. European Journal of Cardio-Thoracic Surgery. 2017;53(4):828–834. doi:10.1093/ejcts/ezx417.
   Web of Science ®Google Scholar
• Johnson DB, Rioth MJ, Horn L. Immune checkpoint inhibitors in NSCLC. Current Treatment Options in Oncology. 2014;15:658–669.
   PubMed Web of Science ®Google Scholar
• He Y, Rozeboom L, Rivard CJ, Ellison K, Dziadziuszko R, Yu H, Zhou C, Hirsch FR. PD-1, PD-L1 protein expression in non-small cell lung cancer and their relationship with tumor-infiltrating lymphocytes. Medical Science Monitor: International Medical Journal of Experimental and Clinical Research. 2017;23:1208. doi:10.12659/MSM.899909.
   PubMed Web of Science ®Google Scholar
• He Y, Rozeboom L, Rivard CJ, Ellison K, Dziadziuszko R, Yu H, Zhou C, Hirsch FR. MHC class II expression in lung cancer. Lung Cancer. 2017;112:75–80. doi:10.1016/j.lungcan.2017.07.030.
   PubMed Web of Science ®Google Scholar
• He Y, Zhang X, Jia K, Dziadziuszko R, Zhao S, Deng J, Wang H, Hirsch FR, Zhou C. OX40 and OX40L protein expression of tumor infiltrating lymphocytes in non-small cell lung cancer and its role in clinical outcome and relationships with other immune biomarkers. Translational Lung Cancer Research. 2019;8(4):352. doi:10.21037/tlcr.2019.08.15.
   PubMed Web of Science ®Google Scholar
• He Y, Jia K, Dziadziuszko R, Zhao S, Zhang X, Deng J, Wang H, Hirsch FR, Zhou C. Galectin-9 in non-small cell lung cancer. Lung Cancer. 2019;136:80–85. doi:10.1016/j.lungcan.2019.08.014.
   PubMed Web of Science ®Google Scholar
• Velcheti V, Rimm DL, Schalper KA. Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1). Journal of Thoracic Oncology. 2013;8(6):803–805. doi:10.1097/JTO.0b013e318292be18.
   PubMed Web of Science ®Google Scholar
• Yang Z, Xu J, Li R, Gao Y, He J. PD-L1 and CD47 co-expression in pulmonary sarcomatoid carcinoma: a predictor of poor prognosis and potential targets of future combined immunotherapy. Journal of Cancer Research and Clinical Oncology. 2019;145(12):3055–3065. doi:10.1007/s00432-019-03023-w.
   PubMed Web of Science ®Google Scholar
• Schenk E, Boland J, Mansfield A, Aubry MC, Dietz A. Local and systemic immunity predict survival in patients with pulmonary sarcomatoid carcinoma. Medical Oncology. 2017;34(8):1–6. doi:10.1007/s12032-017-1000-8.
   PubMed Web of Science ®Google Scholar
• Vieira T, Girard N, Ung M, Monnet I, Cazes A, Bonnette P, Duruisseaux M, Mazieres J, Antoine M, Cadranel J. Efficacy of first-line chemotherapy in patients with advanced lung sarcomatoid carcinoma. Journal of Thoracic Oncology. 2013;8(12):1574–1577. doi:10.1097/01.JTO.0000437008.00554.90.
   PubMed Web of Science ®Google Scholar
• Bae H-M, Min HS, Lee S-H, Kim D-W, Chung DH, Lee J-S, Kim YW, Heo DS. Palliative chemotherapy for pulmonary pleomorphic carcinoma. Lung Cancer. 2007;58(1):112–115. doi:10.1016/j.lungcan.2007.05.006.
   PubMed Web of Science ®Google Scholar
• Domblides C, Leroy K, Monnet I, Mazières J, Barlesi F, Gounant V, Baldacci S, Mennecier B, Toffart A-C A-VC, Audigier-Valette C. Efficacy of immune checkpoint inhibitors in lung sarcomatoid carcinoma. Journal of Thoracic Oncology. 2020;15(5):860–866. doi:10.1016/j.jtho.2020.01.014.
   PubMed Web of Science ®Google Scholar
• Jin C, Yang B. Dramatic response of pulmonary sarcomatoid carcinoma to nivolumab combined with anlotinib: a case report. Case Reports in Oncology. 2020;13(2):601–605. doi:10.1159/000507568.
   PubMed Web of Science ®Google Scholar
• Marmarelis ME, Aggarwal C. Combination immunotherapy in non-small cell lung cancer. Current Oncology Reports. 2018;20(7):55. doi:10.1007/s11912-018-0697-7.
   PubMed Web of Science ®Google Scholar
• Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research. 2004;10(21):7252–7259. doi:10.1158/1078-0432.CCR-04-0713.
   PubMed Web of Science ®Google Scholar
• Qi Y. Random forest for bioinformatics. Ensemble Machine Learning: Springer. 2012;307–323.
   Google Scholar
• Chawla NV, Bowyer KW, Hall LO, Kegelmeyer WP. SMOTE: synthetic minority over-sampling technique. Journal of Artificial Intelligence Research. 2002;16:321–357. doi:10.1613/jair.953.
   Web of Science ®Google Scholar
• Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al.. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proceedings of the National Academy of Sciences. 2005;102(43):15545–15550. doi:10.1073/pnas.0506580102.
   PubMed Web of Science ®Google Scholar
• Shannon P. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Research. 2003;13(11):2498–2504. doi:10.1101/gr.1239303.
   PubMed Web of Science ®Google Scholar
• Miao Y-R, Zhang Q, Lei Q, Luo M, Xie G-Y, Wang H, Guo A-Y. ImmuCellAI: a unique method for comprehensive T-cell subsets abundance prediction and its application in cancer immunotherapy. Advanced Science. 2020;7(7):1902880. doi:10.1002/advs.201902880.
   Web of Science ®Google Scholar
• Chen B, Khodadoust MS, Liu CL, Newman AM, Alizadeh AA. Profiling tumor infiltrating immune cells with CIBERSORT. Cancer systems biology: Springer. 2018. 243–259.
   Google Scholar
• Yao H, Wang H, Li C, Fang JY, Xu J. Cancer Cell-Intrinsic PD-1 and implications in combinatorial immunotherapy. Front Immunol. 2018;9:1774. doi:10.3389/fimmu.2018.01774.
   PubMed Web of Science ®Google Scholar
• Chen P, Zhang L, Zhang W, Sun C, Wu C, He Y, Zhou C. Galectin-9-based immune risk score model helps to predict relapse in stage I–III small cell lung cancer. Journal for Immunotherapy of Cancer. 2020;8(2):2. doi:10.1136/jitc-2020-001391.
   Web of Science ®Google Scholar
• Wang K, Chen Z, Wu R, Yin J, Fan M, Xu X. Prognostic role of high gal-9 expression in solid tumours: a meta-analysis. Cellular Physiology and Biochemistry. 2018;45(3):993–1002. doi:10.1159/000487294.
   PubMedGoogle Scholar
• Takeuchi M, Miyoshi H, Asano N, Yoshida N, Yamada K, Yanagida E, Moritsubo M, Nakata M, Umeno T, Suzuki T. Human leukocyte antigen class II expression is a good prognostic factor in adult T-cell leukemia/lymphoma. haematologica. 2019;104(8):1626. doi:10.3324/haematol.2018.205567.
   PubMed Web of Science ®Google Scholar
• Dunne MR, Phelan JJ, Michielsen AJ, Maguire AA, Dunne C, Martin P, Noonan S, Tosetto M, Geraghty R, Fennelly D. Characterising the prognostic potential of HLA-DR during colorectal cancer development. Cancer Immunology, Immunotherapy. 2020;69(8):1577–1588. doi:10.1007/s00262-020-02571-2.
   PubMed Web of Science ®Google Scholar
• Forero A, Li Y, Chen D, Grizzle WE, Updike KL, Merz ND, Downs-Kelly E, Burwell TC, Vaklavas C, Buchsbaum DJ. Expression of the MHC class II pathway in triple-negative breast cancer tumor cells is associated with a good prognosis and infiltrating lymphocytes. Cancer Immunology Research. 2016;4(5):390–399. doi:10.1158/2326-6066.CIR-15-0243.
   PubMed Web of Science ®Google Scholar
• Nagahara K, Arikawa T, Oomizu S, Kontani K, Nobumoto A, Tateno H, Watanabe K, Niki T, Katoh S, Miyake M. Galectin-9 increases Tim-3+ dendritic cells and CD8+ T cells and enhances antitumor immunity via galectin-9-Tim-3 interactions. The Journal of Immunology. 2008;181:7660–7669.
   PubMed Web of Science ®Google Scholar
• Huang X, Bai X, Cao Y, Wu J, Huang M, Tang D, Tao S, Zhu T, Liu Y, Yang Y. Lymphoma endothelium preferentially expresses Tim-3 and facilitates the progression of lymphoma by mediating immune evasion. Journal of Experimental Medicine. 2010;207(3):505–520. doi:10.1084/jem.20090397.
   PubMed Web of Science ®Google Scholar
• Axelrod ML, Cook RS, Johnson DB, Balko JM. Biological consequences of MHC-II expression by tumor cells in cancer. Clinical Cancer Research. 2019;25(8):2392–2402. doi:10.1158/1078-0432.CCR-18-3200.
   PubMed Web of Science ®Google Scholar
• Accolla RS, Ramia E, Tedeschi A, Forlani G. CIITA-driven MHC class II expressing tumor cells as antigen presenting cell performers: toward the construction of an optimal anti-tumor vaccine. Frontiers in Immunology. 2019;10:1806. doi:10.3389/fimmu.2019.01806.
   PubMed Web of Science ®Google Scholar
• Saraiva DP, Jacinto A, Borralho P, Braga S. 2018. In cytotoxic T lymphocytes predicts breast cancer patients’ response to neoadjuvant chemotherapy. Frontiers in Immunology. Vol. 9. 2605. Cabral MG. HLA-DR.
   Google Scholar
• Costantino CM, Spooner E, Ploegh HL, Hafler DA, Albert ML. Class II MHC self-antigen presentation in human B and T lymphocytes. PLOS ONE. 2012;7(1):e29805. doi:10.1371/journal.pone.0029805.
   PubMed Web of Science ®Google Scholar
• Shivhare SB, Bulmer JN, Lash GE. Chapter 114 - Immunity at the maternal–fetal interface. In: Mestecky J, Strober W, Russell MW, Kelsall BL, Cheroutre H, Lambrecht BN, editors. Mucosal Immunology (Fourth Edition). Boston: Academic Press; 2015. p. 2231–2250. Massachusetts/U.S.A.
   Google Scholar
• Baecher-Allan C, Wolf E, Hafler DA. MHC class II expression identifies functionally distinct human regulatory T cells. Journal of Immunology (Baltimore, Md.: 1950). 2006;176(8):4622–4631. doi:10.4049/jimmunol.176.8.4622.
   PubMed Web of Science ®Google Scholar
• Tsukumo S-i YK, Yasutomo K. Regulation of CD8+ T cells and antitumor immunity by notch signaling. Frontiers in Immunology. 2018;9:101. doi:10.3389/fimmu.2018.00101.
   PubMed Web of Science ®Google Scholar
• Taube JM. Emerging immunologic biomarkers: setting the (TNM-immune) stage. Clinical Cancer Research. 2014;20(8):2023–2025. doi:10.1158/1078-0432.CCR-14-0328.
   PubMed Web of Science ®Google Scholar
• Donnem T, Hald SM, Paulsen -E-E, Richardsen E, Al-Saad S, Kilvaer TK, Brustugun OT, Helland A, Lund-Iversen M, Stromal PM. CD8+ T-cell density—a promising supplement to TNM staging in non–small cell lung cancer. Clinical Cancer Research. 2015;21(11):2635–2643. doi:10.1158/1078-0432.CCR-14-1905.
   PubMed Web of Science ®Google Scholar
• Catacchio I, Scattone A, Silvestris N, Mangia A. Immune prophets of lung cancer: the prognostic and predictive landscape of cellular and molecular immune markers. Translational Oncology. 2018;11(3):825–835. doi:10.1016/j.tranon.2018.04.006.
   PubMed Web of Science ®Google Scholar
• Donnem T, Kilvaer T, Andersen S, Richardsen E, Paulsen E, Hald S, Al-Saad S, Brustugun OT, Helland A, Lund-Iversen M. Strategies for clinical implementation of TNM-Immunoscore in resected nonsmall-cell lung cancer. Annals of Oncology. 2016;27(2):225–232. doi:10.1093/annonc/mdv560.
   PubMed Web of Science ®Google Scholar
• Krummel MF, Bartumeus F, Gérard A. T cell migration, search strategies and mechanisms. Nature Reviews Immunology. 2016;16(3):193. doi:10.1038/nri.2015.16.
   PubMed Web of Science ®Google Scholar
• Okegawa T, Pong RC, Li Y, Hsieh JT. The role of cell adhesion molecule in cancer progression and its application in cancer therapy. Acta biochimica Polonica. 2004;51(2):445–457. doi:10.18388/abp.2004_3583.
   PubMed Web of Science ®Google Scholar
• Sangwan V, Park M. Receptor tyrosine kinases: role in cancer progression. Current Oncology. 2006;13(5):191. doi:10.3390/curroncol13050019.
   PubMedGoogle Scholar
• Katz SG, Rabinovich PM. T cell reprogramming against cancer. Cell reprogramming for immunotherapy: Springer. 2020. 3–44.
   Google Scholar
• Broekman F. Tyrosine kinase inhibitors: multi-targeted or single-targeted?. World Journal of Clinical Oncology. 2011;2(2):80. doi:10.5306/wjco.v2.i2.80.
   PubMedGoogle Scholar
• Nakaoka HJ, Hara T, Yoshino S, Kanamori A, Matsui Y, Shimamura T, Sato H, Murakami Y, Seiki M, Sakamoto T. NECAB3 promotes activation of hypoxia-inducible factor-1 during normoxia and enhances tumourigenicity of cancer cells. Scientific Reports. 2016;6(1):1–13. doi:10.1038/srep22784.
   PubMed Web of Science ®Google Scholar
• Yuan M, Zhu H, Xu J, Zheng Y, Cao X, Liu LQ. Tumor-Derived CXCL1 promotes lung cancer growth via recruitment of tumor-associated neutrophils. Journal of Immunology Research. 2016;2016:2016. doi:10.1155/2016/6530410.
   Web of Science ®Google Scholar
• Manfroi B, Moreaux J, Righini C, Ghiringhelli F, Sturm N, Huard B. Tumor-associated neutrophils correlate with poor prognosis in diffuse large B-cell lymphoma patients. Blood Cancer Journal. 2018;8(7):66. doi:10.1038/s41408-018-0099-y.
   PubMed Web of Science ®Google Scholar
• Jaillon S, Ponzetta A, Di Mitri D, Santoni A, Bonecchi R, Mantovani A. Neutrophil diversity and plasticity in tumour progression and therapy. Nature Reviews Cancer. 2020;20:485–503.
   PubMed Web of Science ®Google Scholar
• Shen M, Hu P, Donskov F, Wang G, Liu Q, Du J. Tumor-associated neutrophils as a new prognostic factor in cancer: a systematic review and meta-analysis. PloS One. 2014;9(6):e98259.
   Web of Science ®Google Scholar
• Nagahara K, Arikawa T, Oomizu S, Kontani K, Nobumoto A, Tateno H, Watanabe K, Niki T, Katoh S, Miyake M, et al.. Galectin-9 Increases Tim-3 + Dendritic Cells and CD8 + T cells and enhances antitumor immunity via galectin-9-Tim-3 interactions. Journal of Immunology (Baltimore, Md.: 1950). 2008;176(8):7660–7669. doi:10.4049/jimmunol.181.11.7660.
   Web of Science ®Google Scholar
• Dudek AM, Martin S, Garg AD, Agostinis P. Immature, semi-mature, and fully mature dendritic cells: toward a DC-cancer cells interface that augments anticancer immunity. Frontiers in Immunology. 2013;4:438. doi:10.3389/fimmu.2013.00438.
   PubMed Web of Science ®Google Scholar
• Eisel D, Das K, Dickes E, König R, Osen W, Eichmüller SB. Cognate interaction with CD4+ T cells instructs tumor-associated macrophages to acquire M1-like phenotype. Frontiers in Immunology. 2019;10:219. doi:10.3389/fimmu.2019.00219.
   PubMed Web of Science ®Google Scholar
• Dhupkar P, Gordon N, Stewart J, Kleinerman ES. Anti-PD-1 therapy redirects macrophages from an M2 to an M1 phenotype inducing regression of OS lung metastases. Cancer Medicine. 2018;7(6):2654–2664. doi:10.1002/cam4.1518.
   PubMed Web of Science ®Google Scholar
• Advani R, Flinn I, Popplewell L, Forero A, Bartlett NL, Ghosh N, Kline J, Roschewski M, LaCasce A, Collins GP. CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin’s lymphoma. New England Journal of Medicine. 2018;379(18):1711–1721. doi:10.1056/NEJMoa1807315.
   PubMed Web of Science ®Google Scholar
• Edris B, Weiskopf K, Volkmer AK, Volkmer J-P, Willingham SB, Contreras-Trujillo H, Liu J, Majeti R, West RB, Fletcher JA. Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma. Proceedings of the National Academy of Sciences. 2012;109(17):6656–6661. doi:10.1073/pnas.1121629109.
   PubMed Web of Science ®Google Scholar
• Willingham SB, Volkmer J-P, Gentles AJ, Sahoo D, Dalerba P, Mitra SS, Wang J, Contreras-Trujillo H, Martin R, Cohen JD. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proceedings of the National Academy of Sciences. 2012;109(17):6662–6667. doi:10.1073/pnas.1121623109.
   PubMed Web of Science ®Google Scholar
• Kl A, Km S, Ito D, Dc L, LJ M, Weiskopf K, NG R, Am R, Shimizu Y, Mescher MF. Evolutionarily conserved resistance to phagocytosis observed in melanoma cells is insensitive to upregulation of pro-phagocytic signals and to CD47 blockade. Melanoma Research. 2020;181(11):147. doi:10.1097/CMR.0000000000000629.
   Google Scholar
• Majeti R, Chao MP, Alizadeh AA, Pang WW, Jaiswal S, Gibbs KD Jr, van Rooijen N, Weissman IL. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell. 2009;138(2):286–299. doi:10.1016/j.cell.2009.05.045.
   PubMed Web of Science ®Google Scholar
• Liu X, Pu Y, Cron K, Deng L, Kline J, Frazier WA, Xu H, Peng H, Fu Y-X, Xu MM. CD47 blockade triggers T cell–mediated destruction of immunogenic tumors. Nature Medicine. 2015;21(10):1209–1215. doi:10.1038/nm.3931.
   PubMed Web of Science ®Google Scholar
• Tseng D, Volkmer J-P, Willingham SB, Contreras-Trujillo H, Fathman JW, Fernhoff NB, Seita J, Inlay MA, Weiskopf K, Anti-CD47 MM. antibody–mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response. Proceedings of the National Academy of Sciences. 2013;110(27):11103–11108. doi:10.1073/pnas.1305569110.
   PubMed Web of Science ®Google Scholar
• Barkal AA, Brewer RE, Markovic M, Kowarsky M, Barkal SA, Zaro BW, Krishnan V, Hatakeyama J, Dorigo O, Barkal LJ, et al.. CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy. Nature. 2019;572(7769):392–396. doi:10.1038/s41586-019-1456-0.
   PubMed Web of Science ®Google Scholar
• Chen GY, Tang J, Zheng P, Liu Y. CD24 and Siglec-10 selectively repress tissue damage-induced immune responses. Science (New York, N.Y.). 2009;110(27):1722–1725. doi:10.1126/science.1168988.
   Web of Science ®Google Scholar